Literature DB >> 7990159

Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model.

J J Casciari1, M G Hollingshead, M C Alley, J G Mayo, L Malspeis, S Miyauchi, M R Grever, J N Weinstein.   

Abstract

BACKGROUND: Cancer treatments that appear promising in tissue culture are often less effective in solid tumors, in part because of the proliferative and microenvironmental heterogeneity that develops in these tumors as they grow. Heterogeneous tumor models are thus needed for drug screening.
PURPOSE: Our goal was to develop and test for drug evaluation a solid tumor model based on cell growth inside biocompatible hollow fibers.
METHODS: Building on the experience of Hollingshead and co-workers with a sparse-cell, hollow-fiber tumor model, we tested six human tumor cell lines for in vitro growth inside 450-microns internal-diameter polyvinylidine fluoride fibers and examined them histologically. Human SW620 colon carcinoma cells grown in hollow fibers were also examined using electron microscopy, and their doxorubicin sensitivity was assessed. A colorimetric assay based on sulforhodamine B was adopted to replace the more cumbersome clonogenic cell survival assay.
RESULTS: Five of the human tumor cell lines tested grew to confluence, forming heterogeneous in vitro tumors with subpopulations of viable and necrotic cells. For SW620 hollow-fiber tumors, maximum viable cell populations in excess of 10(8) cells/mL were obtained after 8 days of growth. This viable cell density remained roughly constant for 3-4 days, permitting dose-response experiments over this time interval. Tumor cells in hollow fibers were much more resistant to a 4-hour doxorubicin exposure than were tumor cells in monolayers: LC50 values (i.e., the drug concentrations at which the plating efficiency equals one-half the plating efficiency of untreated cells) of 3.5 microM and 0.16 microM were obtained for hollow-fiber tumors and monolayers, respectively. LC50 values decreased when drug exposure time was increased. Results from the colorimetric assay were in agreement with those from the clonogenic assay.
CONCLUSION: The successful growth of tumor cells to confluence in hollow fibers and the feasibility of performing in vitro drug dose-response experiments with a relatively easy colorimetric assay demonstrate the potential of the hollow-fiber solid tumor model as a tool for experimental therapeutic research. IMPLICATION: Hollow-fiber solid tumors may prove useful for experimental drug evaluation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7990159     DOI: 10.1093/jnci/86.24.1846

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  20 in total

Review 1.  Preclinical development of molecular-targeted agents for cancer.

Authors:  Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal:  Nat Rev Clin Oncol       Date:  2010-12-07       Impact factor: 66.675

Review 2.  Current status and contemporary approaches to the discovery of antitumor agents from higher plants.

Authors:  Garima Agarwal; Peter J Blanco Carcache; Ermias Mekuria Addo; A Douglas Kinghorn
Journal:  Biotechnol Adv       Date:  2019-01-08       Impact factor: 14.227

3.  Goyazensolide Induces Apoptosis in Cancer Cells in vitro and in vivo.

Authors:  Ulyana Muñoz Acuña; Qi Shen; Yulin Ren; Daniel D Lantvit; Jennifer A Wittwer; A Douglas Kinghorn; Steven M Swanson; Esperanza J Carcache de Blanco
Journal:  Int J Cancer Res       Date:  2013

Review 4.  Discovery of Anticancer Agents of Diverse Natural Origin.

Authors:  A Douglas Kinghorn; Esperanza J Carcache DE Blanco; David M Lucas; H Liva Rakotondraibe; Jimmy Orjala; D Doel Soejarto; Nicholas H Oberlies; Cedric J Pearce; Mansukh C Wani; Brent R Stockwell; Joanna E Burdette; Steven M Swanson; James R Fuchs; Mitchell A Phelps; Lihui Xu; Xiaoli Zhang; Young Yongchun Shen
Journal:  Anticancer Res       Date:  2016-11       Impact factor: 2.480

5.  Multicellular membranes as an in vitro model for extravascular diffusion in tumours.

Authors:  D S Cowan; K O Hicks; W R Wilson
Journal:  Br J Cancer Suppl       Date:  1996-07

6.  Correlative effect between in vivo hollow fiber assay and xenografts assay in drug screening.

Authors:  Keyong Ho Lee; Ki Hyeong Rhee
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

7.  BIOLOGICALLY ACTIVE NATURAL PRODUCTS OF THE GENUS CALLICARPA.

Authors:  William P Jones; A Douglas Kinghorn
Journal:  Curr Bioact Compd       Date:  2008-06-01

8.  Microfabricated polymeric vessel mimetics for 3-D cancer cell culture.

Authors:  Ashley A Jaeger; Chandan K Das; Nicole Y Morgan; Randall H Pursley; Philip G McQueen; Matthew D Hall; Thomas J Pohida; Michael M Gottesman
Journal:  Biomaterials       Date:  2013-07-30       Impact factor: 12.479

9.  Discovery of anticancer agents of diverse natural origin.

Authors:  A Douglas Kinghorn; Esperanza J Carcache de Blanco; Hee-Byung Chai; Jimmy Orjala; Norman R Farnsworth; D Doel Soejarto; Nicholas H Oberlies; Mansukh C Wani; David J Kroll; Cedric J Pearce; Steven M Swanson; Robert A Kramer; William C Rose; Craig R Fairchild; Gregory D Vite; Stuart Emanuel; David Jarjoura; Frederick O Cope
Journal:  Pure Appl Chem       Date:  2009-01-01       Impact factor: 2.453

10.  Control of 3-dimensional collagen matrix polymerization for reproducible human mammary fibroblast cell culture in microfluidic devices.

Authors:  Kyung Eun Sung; Gui Su; Carolyn Pehlke; Steven M Trier; Kevin W Eliceiri; Patricia J Keely; Andreas Friedl; David J Beebe
Journal:  Biomaterials       Date:  2009-06-21       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.